Responsible Respiratory Prescribing

Size: px
Start display at page:

Download "Responsible Respiratory Prescribing"

Transcription

1 Responsible Respiratory Prescribing Dr Vincent Mak Consultant Physician in Respiratory Integrated Care Imperial College Healthcare and Central London Community Healthcare NHS Trust NHS England (London) Respiratory Clinical Leadership Group IPCRG Athens May

2 Disclosures for Dr Vincent Mak In compliance with COI policy, IPCRG 2014 requires the following disclosures to the session audience: Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria No relevant conflicts of interest to declare No relevant conflicts of interest to declare Secondary Care consultant working in Primary Care No relevant conflicts of interest to declare No relevant conflicts of interest to declare AZ, GSK, Boehringer Ingelheim, Novartis Scientific Advisory Board No relevant conflicts of interest to declare Presentation includes discussion of the following off-label use of a drug or medical device: Nil

3 Responsible Prescribing should be based on: Evidence- Based Efficacy (Grade A) Safety (primum non nocere) Value (cost effec>veness) clinicians will need to accept that they are responsible for the stewardship of resources and not just their use Sir Muir Gray BMJ Oct

4 Value Framework Health Outcomes Value = Health Outcomes Cost of delivering Outcomes Cost Porter ME; Lee TH NEJM 2010;363: ;

5 RIGHT CARE RIGHT CARE Do the right thing Do the right thing right Doing the right thing right first -me should deliver quality and value

6 ADDING VALUE by RIGHT CARE High Value High Value High Value Low Value Low Value Added value from doing things right (quality improvement) Added value from doing the right things (making the right decisions)

7 COPD London Respiratory Team Value Pyramid - Cost/QALY

8 To understand VALUE you have to know COST

9 Top 5 Costliest drugs in the NHS (June 2013)? 5. Sere-de 125 evohaler - 81 million/yr 4. Sere-de 500 accuhaler - 85 million/yr 3. Symbicort million/yr 2. Tiotropium million/yr 1. Sere>de 250 evohaler million/yr Total for high potency Seretide: 265million Source:

10 Top 5 Costliest drugs in the NHS (Dec 2013)? 5. Sere-de 125 evohaler - 71 million/yr 4. Sere-de 500 accuhaler - 94 million/yr 3. Symbicort million/yr 2. Sere-de million/yr 1. Tiotropium million/yr Thus, the top 5 costliest drugs to the NHS currently, ALL ARE RESPIRATORY INHALERS Total for high potency Seretide: 252million Source: NHSBSA

11

12 12

13 Are we doing the right thing?

14 COPD London Respiratory Team Value Pyramid - Cost/QALY

15 Doing the right thing? 15 NHS Presentation to [XXXX Company] [Type Date]

16 16 Doing the right thing 2?

17 Evidence Based Prescribing?

18 BTS/SIGN Asthma Guidelines Does this mean majority of asthmatics are at Step 4+ of BTS guidelines?

19 COPD NICE Guidance

20 Evidence of Overuse of Inhaled Cor>costeroids in COPD De la Rosa et al. ERJ 2011: P4627

21 Evidence from UK White P et al. PLoS One Oct 23;8(10):e doi: /journal.pone ecollection 2013.

22 COPD London Respiratory Team Value Pyramid - Cost/QALY

23 The low value pyramid? Representation based on national GP contract data and locally retrieved data

24 Are we doing it right?

25 Doing the Right Things Right Inhaler Technique In some studies, up to 90% of pa-ents may not be able to use an MDI effec-vely 91% of healthcare professionals who teach use of an MDI cannot demonstrate it correctly* Even with effec-ve technique, lung deposi-on from an MDI is at best 12% (excluding newer fine par-cle inhalers)** Large volume spacer may be easier to use and may increase deposi-on to over 20%** If used incorrectly a lot of the drug from MDI is wasted *Thorax 2010;65:A117 ** Newman S. Chest 1985; 88: 152S-160S

26 ] Is it Safe?

27 Risks of high dose ICS HPA suppression D Price et al. Prim Care Respir J 2012;

28 What can we do?

29 Responsible Respiratory Prescribing Key Messages 1. Respiratory medica>ons are expensive Doing the Right Things: 2. When prescribing any new respiratory inhaler, ensure that the pa-ent has undergone NICE- recommended support to stop smoking 3. Pulmonary rehabilita-on is a cost effec-ve alterna-ve to stepping up to triple therapy and should be the preferred op-on if available and the pa-ent is suitable. Doing the Right Things Right: 4. When prescribing any inhaled medica-on, ensure that the pa-ent has undergone pa-ent centred educa-on about the disease and inhaler technique training by a competent trainer 5. When prescribing an MDI (except salbutamol), ensure that a spacer is also prescribed and will be used 6. When prescribing high dose inhaled cor-costeroids (>1000ug BDP equivalent?), ensure that the pa-ent is issued with an inhaled steroid safety card

30 Minimise Risk : Patient Safety Warn about poten>al for adrenal suppression on high doses of ICS Warn about not stopping high dose ICS suddenly

31 Minimise Risk : Minimise waste : Maximise Value Warn about high dose ICS side effects: Pneumonia Diabetes Bone Loss Adrenal Suppression In COPD moderate dose ICS (800µg BDP equivalent) same clinical efficacy as very high dose ICS (2000µg BDP equivalent). In asthma lible evidence for efficacy of ICS above 800µg/day (BTS/SIGN Grade D evidence) Checking inhaler technique, using ICS through a spacer or changing inhaler device may be more effec>ve than increasing the dose or stepping up treatment If dose of ICS has been stepped up in the treatment of asthma and pa>ent is well controlled consider stepping down acer 3 months.

32 Minimise Risk : Increase awareness Traffic light reference card BDP dose equivalence Which inhalers and at what dose may deliver >1000µg BDP equivalent/day Also gives some idea of cost for BDP equivalent doses of different brands of inhaler

33 Inhaled Corticosteroid Safety Card Increase awareness amongst prescribers of: Waste Risk Value Make prescribers aware of alternatives before high dose ICS May change prescribing behaviour as uncomfortable discussion with patient about risk vs benefit

34 It can be done!?

35 Thank You Grainne D Ancona Principal Pharmacist and Honorary Clinical Lecturer St. Thomas' Hospital London, SE1 7EH Colleagues on London Respiratory Team

Responsible Respiratory Prescribing

Responsible Respiratory Prescribing Responsible Respiratory Prescribing Dr Vincent Mak Consultant Physician in Respiratory Integrated Care Imperial College Healthcare and Central London Community Healthcare NHS Trust NHS England (London)

More information

Responsible Respiratory Prescribing

Responsible Respiratory Prescribing Responsible Respiratory Prescribing Dr Vincent Mak Consultant Physician in Respiratory Integrated Care Imperial College Healthcare and Central London Community Healthcare NHS Trust Respiratory Clinical

More information

Responsible Respiratory Prescribing in Primary Care

Responsible Respiratory Prescribing in Primary Care 1 Responsible Respiratory Prescribing in Primary Care Dr Vincent Mak Consultant Physician in Respiratory Integrated Care Imperial College Healthcare NHS Trust Medicines Management Co-Lead, NHSE London

More information

RightBreathe to help with inhaler prescribing and technique

RightBreathe to help with inhaler prescribing and technique www.rightbreathe.com RightBreathe to help with inhaler prescribing and technique Dr Azhar Saleem GP Respiratory Lead, Lambeth CCG GP Specialist NHS London Procurement Partnership Clinical Lead RightBreathe

More information

Include patients: with a confirmed diagnosis of asthma who have been free of asthma symptoms for 3 months or more.

Include patients: with a confirmed diagnosis of asthma who have been free of asthma symptoms for 3 months or more. Corby Clinical Commissioning Group Kettering General Hospital NHS Trust Nene Clinical Commissioning Group rthampton General Hospital NHS Trust rthamptonshire Healthcare Foundation Trust Stepping down asthma

More information

Asthma: Room for improvement in management. Hasanin Khachi Lead Respiratory Medicine Pharmacist Barts Health NHS Trust July 2014

Asthma: Room for improvement in management. Hasanin Khachi Lead Respiratory Medicine Pharmacist Barts Health NHS Trust July 2014 Asthma: Room for improvement in management Hasanin Khachi Lead Respiratory Medicine Pharmacist Barts Health NHS Trust July 2014 Challenges that the NHS faces are well documented What are the challenges?

More information

Inhaled Corticosteroids for the Treatment of Chronic Asthma in Adults & Adolescents aged 12 years & over

Inhaled Corticosteroids for the Treatment of Chronic Asthma in Adults & Adolescents aged 12 years & over Manufacturer Submission To The National Institute for Health and Clinical Excellence By GlaxoSmithKline UK Inhaled Corticosteroids for the Treatment of Chronic Asthma in Adults & Adolescents aged 12 years

More information

Adult Summary flowchart for Asthma Switch and Step Down to ENHCCG preferred inhaler choices

Adult Summary flowchart for Asthma Switch and Step Down to ENHCCG preferred inhaler choices ENHCCG Adult Asthma Switch and Step Down Algorithms - Approved by Hertfordshire Medicines Management Committee June 2016 Page 1 of 6 Adult Summary flowchart for Asthma Switch and Step Down to ENHCCG preferred

More information

Adult Summary flowchart for Asthma Switch and Step Down to preferred inhaler choices

Adult Summary flowchart for Asthma Switch and Step Down to preferred inhaler choices HVCCG Adult Asthma Switch and Step Down Algorithms - Approved by Hertfordshire Medicines Management Committee June 2016 Page 1 of 6 Adult Summary flowchart for Asthma Switch and Step Down to preferred

More information

BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE

BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE December 2014 Review Date: December 2017 Bulletin 206 : DuoResp Spiromax 160 / 4.5 and 320 / 9 budesonide & formoterol dry powder inhaler JPC Recommendations

More information

beclometasone 100 MDI 2 puffs twice a day (recently changed to non CFC (Clenil Modulite))

beclometasone 100 MDI 2 puffs twice a day (recently changed to non CFC (Clenil Modulite)) Case 1 Mr Thomson, a 32 year old asthmatic who is well known to you comes into your pharmacy. He is known to have a best peak flow of 640 L/min. He tells you that over the last few weeks he has been wakening

More information

Stepping-down combination ICS/LABA asthma inhaler therapy: Adults 18yrs

Stepping-down combination ICS/LABA asthma inhaler therapy: Adults 18yrs Step Down guidance Stepping-down combination ICS/LABA asthma inhaler therapy: Adults 18yrs Important Complete asthma control needs to be achieved for at least 12 weeks before attempting to step patients

More information

Position within the Organisation

Position within the Organisation ASTHMA TREATMENT GUIDELINES Document Description Document Type Service Application Guidelines All healthcare professionals(hcps) caring for patients with asthma Version 4.0 Ratification date September

More information

The clinical effectiveness and costeffectiveness. treatment of chronic asthma in children under the age of 12 years

The clinical effectiveness and costeffectiveness. treatment of chronic asthma in children under the age of 12 years The clinical effectiveness and costeffectiveness of corticosteroids for the treatment of chronic asthma in children under the age of 12 years Submission of evidence from AstraZeneca UK Ltd regarding the

More information

Error! No text of specified style in document.

Error! No text of specified style in document. Inhaled corticosteroids and long-acting beta 2 -agonists for the treatment of chronic asthma in children under the age of 12 years: Systematic review and economic analysis Amended cost-off set comparisons

More information

Not available 100/6mcg 2 BD formoterol (Fostair MDI) 100/6mcg 33

Not available 100/6mcg 2 BD formoterol (Fostair MDI) 100/6mcg 33 COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP FLUTICASONE FUROATE/VILANTEROL COMBINATION INHALER - ASTHMA Policy agreed by Vale of York CCG (date) Drug, Treatment, Device name Fluticasone

More information

Stepping down asthma treatment guidelines

Stepping down asthma treatment guidelines Stepping down asthma treatment guidelines The potential for inhaled corticosteroids (ICS) to cause dose-related side-effects has led to asthma management guidelines recommending a dose reduction once asthma

More information

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES Document Description Document Type Service Application Version Guidelines All healthcare professionals(hcps) caring for patients with asthma

More information

Prescribing guidelines: Management of COPD in Primary Care

Prescribing guidelines: Management of COPD in Primary Care Prescribing guidelines: Management of COPD in Primary Care Establish diagnosis of COPD in patients 35 years with appropriate symptoms with history, examination and spirometry (FEV1/FVC ratio < 70%) Establish

More information

Chapter 3: Respiratory System (7 th Edition)

Chapter 3: Respiratory System (7 th Edition) Chapter 3: Respiratory System (7 th Edition) The Sheffield respiratory guidelines (April 2015) have been removed from the intranet. This is because the COPD section has been superseded by the COPD treatment

More information

Chronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines

Chronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines Chronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines Where appropriate the following should be offered before commencing inhaled treatment: Offer treatment and support to stop smoking. Smoking

More information

Ivax Pharmaceuticals UK Sponsor Submission to the National Institute for Health and Clinical Excellence

Ivax Pharmaceuticals UK Sponsor Submission to the National Institute for Health and Clinical Excellence Ivax Pharmaceuticals UK Sponsor Submission to the National Institute for Health and Clinical Excellence Clinical and cost-effectiveness of QVAR for the treatment of chronic asthma in adults and children

More information

Seretide 250mcg/125mcg Evohaler switch to Fostair 100/6 MDI in COPD.

Seretide 250mcg/125mcg Evohaler switch to Fostair 100/6 MDI in COPD. Seretide 250mcg/125mcg Evohaler switch to Fostair 100/6 MDI in COPD. Applies to HaRD CCG employed Pharmacists and Medicines Optimisation Technicians These protocols are produced by the NY&AWC MM team hosted

More information

Bronchodilator Delivery and Nebuliser Trials in Adults

Bronchodilator Delivery and Nebuliser Trials in Adults Bronchodilator Delivery and Nebuliser Trials in Adults Acute Management Favour the use of MDI (+/- Spacer) If considering nebuliser Short term treatment Approx. < 3 weeks See optimisation of inhaled bronchodilators

More information

Greater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma

Greater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma Greater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma Non-pharmacological options for ALL patients, consider at ALL stages Make sure diagnosis

More information

THEOPHYLLINE WITH INHALED CORTICOSTEROIDS (TWICS) TRIAL SELF MANAGMENT / ACTION PLANS GENUAIR INHALERS: POTENTIAL SAFETY ISSUE

THEOPHYLLINE WITH INHALED CORTICOSTEROIDS (TWICS) TRIAL SELF MANAGMENT / ACTION PLANS GENUAIR INHALERS: POTENTIAL SAFETY ISSUE I S S U E 4 M A R C H / A R P I L 2 0 1 6 Endorsed December 2014 I N S I D E T H I S I S S U E : Theophylline with Inhaled Corticosteroids (TWICS) Trial Genuair Inhaler: Potential Safety Issue 1 Self Management

More information

Dr Christopher Worsnop

Dr Christopher Worsnop Dr Christopher Worsnop Respiratory & Sleep Physician Austin Hospital, Melbourne Supported by: Top Tips in Modern Asthma Management Dr Christopher Worsnop Rotorua GPCME Meeting June 2013 Speaker declaration

More information

Progress, Paediatrics and Protocols. Dr Andy Powell Dr Lesley Ayling West Hampshire CCG

Progress, Paediatrics and Protocols. Dr Andy Powell Dr Lesley Ayling West Hampshire CCG Progress, Paediatrics and Protocols Dr Andy Powell Dr Lesley Ayling West Hampshire CCG Progress Solutions CQUIN discharge bundle (including personal action plan), specialist review, immediate management

More information

Breakfast Session Prof Neil Barnes Professor of Respiratory Medicine London Chest Hospital & The Royal London Hospital United Kingdom

Breakfast Session Prof Neil Barnes Professor of Respiratory Medicine London Chest Hospital & The Royal London Hospital United Kingdom Breakfast Session Prof Neil Barnes Professor of Respiratory Medicine London Chest Hospital & The Royal London Hospital United Kingdom 2 BEYOND SYMPTOMS ADDRESSING FUTURE RISK IN ASTHMA South GP CME 2013,

More information

CHARM ASTHMA TREATMENT GUIDELINE

CHARM ASTHMA TREATMENT GUIDELINE NHS City and Hackney Prescribing Guidelines Adults ( 12 years of age) CHARM ASTHMA TREATMENT GUIDELINE Written by: Hetal Dhruve (Specialist Respiratory Pharmacist, City and Hackney CCG) Checked by: Prof

More information

ASTHMA PRESCRIBING GUIDELINES FOR ADULTS AND CHILDREN OVER 12

ASTHMA PRESCRIBING GUIDELINES FOR ADULTS AND CHILDREN OVER 12 North Hampshire CCG Asthma Prescribing Guidelines June 2015 ASTHMA PRESCRIBING GUIDELINES FOR ADULTS AND CHILDREN OVER 12 These guidelines are based on the British Thoracic Society (BTS) and Scottish Intercollegiate

More information

ASTHMA TREATMENT GUIDE (ADULTS)

ASTHMA TREATMENT GUIDE (ADULTS) ASTHMA TREATMENT GUIDE (ADULTS) The BTS/SIGN guideline provides a wide range of information and guidance on the treatment of patients with asthma. https://www.brit-thoracic.org.uk/document-library/clinical-information/asthma/btssign-asthma-guideline-2016/

More information

Guide to Inhaled Treatment Choices

Guide to Inhaled Treatment Choices Guide to Inhaled Treatment Choices Note: this is guidance only, it is important to consider which device is best suited to the patient. This may NOT be the first line choice (but should be on the joint

More information

Yorkshire & Humber Respiratory Programme Report

Yorkshire & Humber Respiratory Programme Report 2013 NHS Bassetlaw Clinical Commissioning Group Yorkshire & Humber Respiratory Programme Report This report has been produced by the Yorkshire & Humber Respiratory Team. It highlights opportunities that

More information

Guide to Inhaled Treatment Choices

Guide to Inhaled Treatment Choices Guide to Inhaled Treatment Choices Note: this is guidance only, it is important to consider which device is best suited to the patient. This may NOT be the first line choice (but should be on the joint

More information

Medicines Optimisation Team Standard Operating Procedure for Audit: High Dose Inhaled Corticosteroids

Medicines Optimisation Team Standard Operating Procedure for Audit: High Dose Inhaled Corticosteroids Cannock Chase Clinical Commissioning Group South East Staffordshire and Seisdon Peninsula Clinical Commissioning Group Stafford and Surrounds Clinical Commissioning Group East Staffordshire Clinical Commissioning

More information

Rosemary Plum Prescriptive Solutions Ltd SIMPLE Respiratory 2015

Rosemary Plum Prescriptive Solutions Ltd SIMPLE Respiratory 2015 + A SERVICE FOR COMMUNITY PHARMACY Rosemary Plum Prescriptive Solutions Ltd + n Why Pharmacy? High patient footfall 450 diagnosed asthma patients Walk-in service Medicines skills and expertise Structured

More information

Asthma Treatment Guideline for Adults (aged 17 and over)

Asthma Treatment Guideline for Adults (aged 17 and over) Asthma Treatment Guideline for Adults (aged 17 and over) Sharon Andrew MLCSU January 2019 (Review date 0 January 2022) VERSION CONTROL. Please access via the LMMG website to ensure that the correct version

More information

Helping Smokers Quit Clinicians adding value from every contact by treating tobacco dependence

Helping Smokers Quit Clinicians adding value from every contact by treating tobacco dependence Helping Smokers Quit Clinicians adding value from every contact by treating tobacco dependence Eg Louise Restrick London Respiratory Network Lead Integrated consultant respiratory physician On behalf of

More information

Compare your care. How asthma care in England matches up to standards R E S P I R AT O R Y S O C I E T Y U K

Compare your care. How asthma care in England matches up to standards R E S P I R AT O R Y S O C I E T Y U K Compare your care How asthma care in England matches up to standards PRIMARY CARE R E S P I R AT O R Y S O C I E T Y U K Asthma matters Around 4.5 million people in England that s 1 in 11 are being treated

More information

Yorkshire & Humber Respiratory Programme Report

Yorkshire & Humber Respiratory Programme Report 2013 NHS Doncaster Clinical Commissioning Group Yorkshire & Humber Respiratory Programme Report This report has been produced by the Yorkshire & Humber Respiratory Team. It highlights opportunities that

More information

Inhaler Standards and Competency Document

Inhaler Standards and Competency Document Inhaler Standards and Competency Document Inhaler Standards and Competency Document Authors: Jane Scullion Respiratory Nurse Consultant University Hospitals of Leicester NHS Trust Monica Fletcher CEO of

More information

Yorkshire & Humber Respiratory Programme Report

Yorkshire & Humber Respiratory Programme Report 2013 NHS Harrogate & Rural District Clinical Commissioning Group Yorkshire & Humber Respiratory Programme Report This report has been produced by the Yorkshire & Humber Respiratory Team. It highlights

More information

Blue, Pink and everything in between: an update on COPD. Tara Lohmann MD FRCPC Division of Respirology University of Calgary

Blue, Pink and everything in between: an update on COPD. Tara Lohmann MD FRCPC Division of Respirology University of Calgary Blue, Pink and everything in between: an update on COPD Tara Lohmann MD FRCPC Division of Respirology University of Calgary Disclosures I have eaten lunches provided by many pharmaceutical companies (GSK,

More information

MeReC Bulletin. MeReC Publications. Vol.22 No.03 January 2012

MeReC Bulletin. MeReC Publications. Vol.22 No.03 January 2012 MeReC Bulletin Vol.22 No.03 January 2012 MeReC Publications Implementing key therapeutic topics: 1 NSAIDs; antibiotics; and inhaled corticosteroids in asthma The QIPP agenda aims to ensure that value for

More information

Treatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark

Treatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting

More information

Treatment choices for patients with asthma or COPD. Jo Riley Lead Nurse For Oxfordshire Respiratory Service

Treatment choices for patients with asthma or COPD. Jo Riley Lead Nurse For Oxfordshire Respiratory Service Treatment choices for patients with asthma or COPD Jo Riley Lead Nurse For Oxfordshire Respiratory Service What is the difference? Is it all about? Inhaled steroids Long acting ß2 agonists Short acting

More information

Yorkshire & Humber Respiratory Programme Report. NHS Hambleton, Richmondshire and Whitby Clinical Commissioning Group

Yorkshire & Humber Respiratory Programme Report. NHS Hambleton, Richmondshire and Whitby Clinical Commissioning Group 2013 NHS Hambleton, Richmondshire and Whitby Clinical Commissioning Group Yorkshire & Humber Respiratory Programme Report This report has been produced by the Yorkshire & Humber Respiratory Team. It highlights

More information

NEBULISERS AND NEBULISED MEDICATION. A Guide for the use of nebulisers and nebulised medication in the community setting

NEBULISERS AND NEBULISED MEDICATION. A Guide for the use of nebulisers and nebulised medication in the community setting NEBULISERS AND NEBULISED MEDICATION A Guide for the use of nebulisers and nebulised medication in the community setting Aim This guide has been developed from the generic guidance circulated in April 2014.

More information

SABA: VENTOLIN EVOHALER (SALBUTAMOL) SAMA: ATROVENT IPRATROPIUM. Offer LAMA (discontinue SAMA) OR LABA

SABA: VENTOLIN EVOHALER (SALBUTAMOL) SAMA: ATROVENT IPRATROPIUM. Offer LAMA (discontinue SAMA) OR LABA COPD GUIDELINES DIAGNOSIS >35 years of age Symptoms of cough, breathlessness, sputum, wheeze, Risk factor (SMOKING) Spirometry (post bronchodilator) FEV1/FVC = 0.7 ENCOURAGE PATIENTS TO BRING INHALERS

More information

Algorithm for the use of inhaled therapies in COPD

Algorithm for the use of inhaled therapies in COPD Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care

More information

Summary of Lothian Joint Formulary Amendments

Summary of Lothian Joint Formulary Amendments Summary of Lothian Joint Formulary Amendments The purpose of this summary is to detail the main changes to the LJF sections and provide additional information on the reasons for some of the changes. The

More information

Title of Project: NHS Dumfries & Galloway Respiratory Bundle Asthma: Bronchodilator Overuse Review April 2015

Title of Project: NHS Dumfries & Galloway Respiratory Bundle Asthma: Bronchodilator Overuse Review April 2015 Title of Project: NHS Dumfries & Galloway Respiratory Bundle Asthma: Bronchodilator Overuse Review April 2015 1 Reason for the review Respiratory prescribing is long term and can be costly. Appropriate

More information

requesting information regarding prescribing incentive schemes in Canterbury and Coastal Clinical Commissioning Group

requesting information regarding prescribing incentive schemes in Canterbury and Coastal Clinical Commissioning Group requesting information regarding prescribing incentive schemes in Canterbury and Coastal Clinical Commissioning Group Canterbury and Coastal Clinical Consortium Group Medicine Management plans 2013/14

More information

ASTRAZENECA v GLAXOSMITHKLINE

ASTRAZENECA v GLAXOSMITHKLINE CASE AUTH/1986/4/07 ASTRAZENECA v GLAXOSMITHKLINE Symbicort and Seretide cost comparisons AstraZeneca complained about cost comparisons made by GlaxoSmithKline between AstraZeneca s Symbicort (budesonide/formoterol)

More information

Medicines Management of Asthma

Medicines Management of Asthma Wandsworth Borough Team Medicines Management of Guidelines for Primary Care September 2011 Version 1 Guideline Authors: Shaneez Dhanji (Wandsworth borough) Reena Rabheru-Dodhy (Sutton & Merton borough)

More information

NHS Northern, Eastern and Western Devon Clinical Commissioning Group NHS South Devon and Torbay Clinical Commissioning Group

NHS Northern, Eastern and Western Devon Clinical Commissioning Group NHS South Devon and Torbay Clinical Commissioning Group NHS Northern, Eastern and Western Devon Clinical Commissioning Group NHS South Devon and Torbay Clinical Commissioning Group Inhaler technique and respiratory conditions Guidance Sheet 16 When diagnosed

More information

Confidence and understanding among general practitioners and practice nurses in the UK about diagnosis and management of COPD

Confidence and understanding among general practitioners and practice nurses in the UK about diagnosis and management of COPD Respiratory Medicine (2007) 101, 2378 2385 Confidence and understanding among general practitioners and practice nurses in the UK about diagnosis and management of COPD D.M.G. Halpin a,, J.F. O Reilly

More information

Long-acting bronchodilators: their properties and place in treatment

Long-acting bronchodilators: their properties and place in treatment Long-acting bronchodilators: their properties and place in treatment Steve Chaplin MSc, MRPharmS and Paul Walker BMedSci (Hons), MD, FRCP Steve Chaplin and Dr Paul KEY POINTS Walker provide an overview

More information

Research in Real Life

Research in Real Life Research in Real Life Study 1: Exploratory study - identifying the benefits of pmdi versus Diskus for delivering fluticasone/salmeterol combination therapy in patients with chronic obstructive pulmonary

More information

Community Pharmacy Asthma Audit 2016/17. Contents

Community Pharmacy Asthma Audit 2016/17. Contents Community Pharmacy Contents Community Pharmacy... 1 Executive Summary... 2 Introduction... 4 Background... 4 Method... 5 Results... 5 Section One: Community Pharmacy Guidelines Awareness and Training...

More information

Plymouth Pharmacy Inhaler Use Review Pilot March 2018

Plymouth Pharmacy Inhaler Use Review Pilot March 2018 Plymouth Pharmacy Inhaler Use Review Pilot March 2018 Tony Perkins Lead respiratory pharmacist Livewell SW Training session location; conference room Boringdon Golf Plympton club (no access to sporting

More information

NHS Dumfries & Galloway Triple therapy in COPD patients over 16 years

NHS Dumfries & Galloway Triple therapy in COPD patients over 16 years Title of Project: NHS Dumfries & Galloway Triple therapy in COPD patients over 16 years 1 Reason for the review Respiratory prescribing is long term and can be costly. Appropriate choice and use of inhaled

More information

Algorithm for the use of inhaled therapies in COPD Version 2 May 2017

Algorithm for the use of inhaled therapies in COPD Version 2 May 2017 Algorithm for the use of inhaled therapies in COPD This document has been revised by the Berkshire West Respiratory Network to support clinicians in selecting the most appropriate, cost effective treatments

More information

Community COPD Service Protocol

Community COPD Service Protocol Community COPD Service Protocol Acknowledgements This protocol is based on the following documents: 1. Chronic obstructive pulmonary disease: Management of chronic obstructive pulmonary disease in adults

More information

Respiratory Inhalers. Identification Guide Version 3

Respiratory Inhalers. Identification Guide Version 3 Respiratory Inhalers Identification Guide Version 3 This booklet has been prepared by NHSGGC Medicines Information. Endorsed by NHSGGC Respiratory Managed Clinical Network, February 2017. Designed by Medical

More information

On completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children

On completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children 7 Asthma Asthma is a common disease in children and its incidence has been increasing in recent years. Between 10-15% of children have been diagnosed with asthma. It is therefore a condition that pharmacists

More information

DR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL

DR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL DR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL Definition Guidelines contact complicated definitions Central to this is Presence of symptoms Variable airflow obstruction Diagnosis

More information

Practical Approach to Managing Paediatric Asthma

Practical Approach to Managing Paediatric Asthma Practical Approach to Managing Paediatric Asthma Dr Andrew Tai FRACP, PhD Paediatric Respiratory and Sleep Specialist Women's and Children's Hospital, Adelaide Approaching the patient Check the diagnosis

More information

3. Respiratory System

3. Respiratory System 1 3. Respiratory System Also see Appendix 3A Guidance on Management of Also see Appendix 3B Preferred Inhaler Devices for Adults Also see Appendix 3C Preferred Inhaler Devices for Adolescents (12-18 years)

More information

COPD Device Workshop. Summary. Role of inhaler device in COPD. Why use inhaler device in COPD?

COPD Device Workshop. Summary. Role of inhaler device in COPD. Why use inhaler device in COPD? Part 1 Role of inhaler device in COPD COPD Device Workshop Dr Philip Lee Respiratory and Sleep Physician St George Hospital, Sydney Part 2 Part 3 Part 4 Incorrect inhaler technique-adverse clinical outcomes

More information

Bulletin Independent prescribing information for NHS Wales

Bulletin Independent prescribing information for NHS Wales Bulletin Independent prescribing information for NHS Wales Respiratory disease September 2014 Respiratory diseases account for one in seven of all deaths in Wales the third largest cause of mortality for

More information

Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing

Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School

More information

And new, additional, challenges are developing RISING EXPECTATIONS INCREASING NEED FINANCIAL CONSTRAINTS CLIMATE CHANGE

And new, additional, challenges are developing RISING EXPECTATIONS INCREASING NEED FINANCIAL CONSTRAINTS CLIMATE CHANGE However, all health services, everywhere, still face 5 major problems one of which is unwarranted variation which is variation in utilization of health care services that cannot be explained by variation

More information

Medicines Management Programme Update

Medicines Management Programme Update Medicines Management Programme Update Sarah Clarke Chief II Pharmacist and Programme Manager Medicines Management Programme (MMP) www.hse.ie/yourmedicines Millions ( ) The Medicines Management Programme

More information

Under 5s asthma action plan

Under 5s asthma action plan Under 5s asthma action plan Keep this plan safe and take it with you every time your child sees their GP or asthma nurse. If you re worried about your child s asthma don t put off asking for help or advice.

More information

Why Asthma Still Kills The National Review of Asthma Deaths (NRAD)

Why Asthma Still Kills The National Review of Asthma Deaths (NRAD) APPROVED FINAL VERSION NHS Protect Why Asthma Still Kills The National Review of Asthma Deaths (NRAD) Summary of Recommendations for GP Practices and Community Pharmacies Author: Anne Henry Contact: anne.henry@nhs.net

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE DRAFT NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Chronic obstructive pulmonary disease: the management of adults with chronic obstructive pulmonary disease in primary

More information

PATIENT INFORMATION Chronic Obstructive Pulmonary Disease (COPD) Fact Sheet

PATIENT INFORMATION Chronic Obstructive Pulmonary Disease (COPD) Fact Sheet PATIENT INFORMATION Chronic Obstructive Pulmonary Disease (COPD) Fact Sheet What is COPD? COPD is a general term, which includes the conditions chronic asthma, chronic bronchitis and emphysema. It is due

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis

More information

Online supplementary material

Online supplementary material Online supplementary material Add-on long-acting β2-agonist (LABA) in a separate inhaler as asthma step-up therapy versus increased dose of inhaled corticosteroid (ICS) or ICS/LABA combination inhaler

More information

A NEBULISERS AND NEBULISED MEDICATION. Generic Guide for the use of nebulisers and nebulised medication

A NEBULISERS AND NEBULISED MEDICATION. Generic Guide for the use of nebulisers and nebulised medication A NEBULISERS AND NEBULISED MEDICATION Generic Guide for the use of nebulisers and nebulised medication Aim The aim of this guide is to provide a template for those who wish to develop their own nebuliser

More information

12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing

12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School

More information

Advanced Inhaler Technique. Learning Outcomes. Disclosure 1.1. Belgian Chocolate, French Champagne and Inhaled Medication: Too Good To Waste?

Advanced Inhaler Technique. Learning Outcomes. Disclosure 1.1. Belgian Chocolate, French Champagne and Inhaled Medication: Too Good To Waste? Advanced Inhaler Technique Learning Outcomes Describe the mechanism of different inhalers Explain how inspiratory flow can effect drug delivery for different inhalers Counsel a patient on the correct use

More information

Leeds West CCG Paediatric asthma project. January 2015-January 2017

Leeds West CCG Paediatric asthma project. January 2015-January 2017 Leeds West CCG Paediatric asthma project. January 2015-January 2017 Aims to raise asthma awareness improve care reduce emergency attendances and unplanned admissions to secondary care for children with

More information

Chronic Obstructive Pulmonary Disease. Information about medication and an Action Plan to use if your condition gets worse due to an infection

Chronic Obstructive Pulmonary Disease. Information about medication and an Action Plan to use if your condition gets worse due to an infection Chronic Obstructive Pulmonary Disease Information about medication and an Action Plan to use if your condition gets worse due to an infection Information about your medication Your usual treatment Inhalers

More information

Address Comorbidities

Address Comorbidities Greater Manchester COPD Management Plan Non-pharmacological management for ALL patients Smoking Cessation Annual Flu Vaccination Pulmonary Rehabilitation Increase daily activity Inhaler Technique Measure

More information

Beclometasone dipropionate (BDP) Prophylactic management of mild, moderate or severe asthma in adults

Beclometasone dipropionate (BDP) Prophylactic management of mild, moderate or severe asthma in adults CLENIL MODULITE Beclometasone dipropionate (BDP) Prophylactic management of mild, moderate or severe asthma in adults Corticosteroids for the treatment of chronic asthma in adults and children aged 12

More information

Allwin Mercer Dr Andrew Zurek

Allwin Mercer Dr Andrew Zurek Allwin Mercer Dr Andrew Zurek 1 in 11 people are currently receiving treatment for asthma (5.4 million people in the UK) Every 10 seconds, someone is having a potentially life-threatening asthma attack

More information

WEBINAR. Difficult-to-treat and severe asthma: changing the paradigm

WEBINAR. Difficult-to-treat and severe asthma: changing the paradigm WEBINAR Difficult-to-treat and severe asthma: changing the paradigm A multidisciplinary discussion on new therapies, and how to identify and manage difficult-to-treat and severe asthma DIFFICULT-TO-TREAT

More information

Patient Group Direction for SALBUTAMOL INHALER (Version 02) Valid From 1 October September 2019

Patient Group Direction for SALBUTAMOL INHALER (Version 02) Valid From 1 October September 2019 Version Control This PGD has been agreed by the following organisations FCMS PDS Medical Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Chronic obstructive pulmonary disease: the management of adults with chronic obstructive pulmonary disease in primary and secondary

More information

Tips on managing asthma in children

Tips on managing asthma in children Tips on managing asthma in children Dr Ranjan Suri Consultant in Respiratory Paediatrics Bupa Cromwell Hospital Clinics: Friday (pm) Asthma in Children Making the diagnosis Patterns of childhood asthma

More information

fluticasone furoate / vilanterol 92/22, 184/22 micrograms inhalation powder (Relvar Ellipta ) SMC No. (966/14) GlaxoSmithKline UK

fluticasone furoate / vilanterol 92/22, 184/22 micrograms inhalation powder (Relvar Ellipta ) SMC No. (966/14) GlaxoSmithKline UK fluticasone furoate / vilanterol 92/22, 184/22 micrograms inhalation powder (Relvar Ellipta ) SMC No. (966/14) GlaxoSmithKline UK 09 May 2014 The Scottish Medicines Consortium (SMC) has completed its assessment

More information

Information for Patients. Inhaler devices for routine treatment of chronic asthma in older children (aged 5-15 years)

Information for Patients. Inhaler devices for routine treatment of chronic asthma in older children (aged 5-15 years) Information for Patients Inhaler devices for routine treatment of chronic asthma in older children (aged 5-15 years) March 2002 Further information Further information on NICE and the full guidance on

More information

COPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health

COPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health COPD: Treatment Update Barry Make, MD Professor of Medicine National Jewish Health Disclosures Advisory board, consultant, multi-center trial, research funding, Data Safety Monitoring Board (DSMB), or

More information

Asthma Tutorial. Trainer MRW. Consider the two scenarios, make an attempt at the questions, what guidance have you used?

Asthma Tutorial. Trainer MRW. Consider the two scenarios, make an attempt at the questions, what guidance have you used? Registrar: LG PR RS Topic Asthma and COPD Asthma Tutorial Trainer MRW Date of Tutorial 18 th Jan 2007 Objectives of the tutorial How to diagnose What investigations and when Treatment guidelines QoF Criteria

More information

Medicines Management of Chronic Obstructive Pulmonary Disease (COPD)

Medicines Management of Chronic Obstructive Pulmonary Disease (COPD) Medicines Management of Chronic Obstructive Pulmonary Disease (COPD) (Chronic & Acute) Guidelines for Primary Care Guideline Authors: Shaneez Dhanji (Wandsworth CCG) Samantha Prigmore (St George s Hospital)

More information